US SB4302 | 2021-2022 | 117th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on May 25 2022 - 25% progression, died in committee
Action: 2022-05-25 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 25 2022 - 25% progression, died in committee
Action: 2022-05-25 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.
Title
Biologics Market Transparency Act of 2022
Sponsors
Sen. Tim Kaine [D-VA] | Sen. Roger Marshall [R-KS] | Sen. Margaret Hassan [D-NH] | Sen. Bill Cassidy [R-LA] |
History
Date | Chamber | Action |
---|---|---|
2022-05-25 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709) |
Same As/Similar To
SB4348 (Related) 2022-07-13 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
HB7035 (Related) 2022-03-10 - Referred to the Subcommittee on Health.
HB7667 (Related) 2022-06-09 - Received in the Senate.
HB7035 (Related) 2022-03-10 - Referred to the Subcommittee on Health.
HB7667 (Related) 2022-06-09 - Received in the Senate.
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/117th-congress/senate-bill/4302/all-info |
Text | https://www.congress.gov/117/bills/s4302/BILLS-117s4302is.pdf |